Mylan Issues Statement in Response to Abbott's Support for Perrigo Transaction


Mylan N.V. today issued a statement regarding Abbott Laboratories' announced intention to support Mylan's offer to acquire Perrigo Company plc.






June 16, 2015

/PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today issued the following statement regarding Abbott Laboratories' (NYSE: ABT) announced intention to support Mylan's offer to acquire Perrigo Company plc (NYSE: PRGO; TASE) and vote in favor of this acquisition at Mylan's upcoming shareholder meeting.


is currently Mylan's largest shareholder, owning 14.5% of Mylan's outstanding shares, and is an important long-term stakeholder of Mylan through various manufacturing partnerships.

Mylan Executive Chairman

Robert J. Coury

stated: "We are very pleased that, while


is under no obligation to do so,


has voluntarily chosen to express its support of Mylan, our strategic growth plan and stand-alone strategy, and our proposed combination with Perrigo. When we acquired


non-U.S. developed markets specialty and branded generics business earlier this year, we gained an important stakeholder in


, which understands the powerful potential of our platform, and the critical importance of our scale and breadth across our distribution channels. We are grateful for


support of our long-term vision, which we firmly believe will continue to deliver strong near-term and long-term returns in this rapidly evolving industry and will promote the sustainable success of Mylan's business."

Related Videos
Whole psilocybin mushroom in a clear medication capsule | Image credit: Zim -
Patient suffering from atopic dermatitis -- Image credit: Nikkikii |
Image credit: Fabio Balbi |
Image credit: Melita -
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская |
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS |
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz -
Image credit: New Africa |
© 2024 MJH Life Sciences

All rights reserved.